ERBB2 and neoplasm: In good agreement, Corgnac et al. demonstrated consistent NKT-cell-mediated antitumor effects through repeated administration of tumor-targeted recombinant sCD1d-antitumor scFv fusion proteins specific for either HER2 or CEA, loaded with α-GalCer [96].